PAH

Showing 5 posts of 5 posts found.

8655563196_1c0f83c447_z

United Therapeutics buys Arena’s hypertension drug ralinepag in deal worth $1.2 billion

November 16, 2018
Medical Communications Arena, PAH, United Therapeutics, deal sales, hypertension

US pharma firm United Therapeutics has agreed to by Arena Pharmaceuticals experimental pulmonary arterial hypertension (PAH) drug ralinepag in a …

Actelion logo

Actelion’s Uptravi goes on sale

January 5, 2016
Manufacturing and Production, Sales and Marketing Actelion, PAH, Uptravi, pulmonary arterial hypertension, pulmonary hypertension, selexipag

Swiss pharma firm Actelion has put its new drug for pulmonary hypertension, Uptravi, up for sale in the US, weeks …

Pfizer

Pfizer’s Revatio extends Europe PAH licence

May 9, 2011
Sales and Marketing PAH, Pfizer, pulmonary arterial hypertension, revatio

Pfizer’s Revatio has been approved by European regulators for the treatment of pulmonary arterial hypertension (PAH) in children.The European Commission has …

Pfizer's New York headquarters

Pfizer withdraws hypertension drug Thelin

December 14, 2010
Sales and Marketing PAH, Pfizer, Thelin, liver damage, liver toxicity, patient safety, pulmonary arterial hypertension, sitaxentan

Pfizer has suffered a blow to its drug development programme with the withdrawal of pulmonary arterial hypertension (PAH) brand Thelin …

Pfizer adds another product to its PAH franchise

May 14, 2010
Research and Development Ergonex, PAH, Pfizer, Thelin, revatio, terguride, viagra

Pfizer has signed an agreement to acquire terguride, a drug for pulmonary arterial hypertension (PAH) currently in phase II testing, …

Latest content